158 million covered lives nationwide bring the FDA-cleared wearable Remote Electrical Neuromodulation (REN) device to coverage parity with leading prescription migraine drugs, following a wave of recent payer coverage expansions.

, /PRNewswire/ -- Theranica, a neuromodulation therapeutics firm focused on improving migraine treatment via its proprietary Remote Electrical Neuromodulation (REN) approach, announced today that insurance coverage for Nerivio, its FDA-cleared therapy for acute and preventive migraine management, has hit 158 million lives across every U.S. state, surpassing half the nation's insured population.

The achievement comes after multiple recent coverage expansions and shows rising payer trust in Nerivio's clinical results and health economic value along with wider adoption in migraine management. Fresh coverage from a leading national health insurer, plus twelve new policies in various states, has doubled Nerivio coverage in the last 15 months, marking one of the quickest reimbursement growth rates for any prescribed therapeutic device.

Consequently, commercial coverage for Nerivio now matches that of top branded prescription migraine medications, an access level seldom attained by prescribed therapeutic devices. More than half of the roughly 314 million Americans with health insurance now have coverage for Nerivio when prescribed per their plan's rules. Nerivio coverage extends across national and regional plans nationwide, delivering the widest commercial reimbursement reach for any prescribed migraine device in the U.S.

"This broader access to Nerivio marks a historic shift in the U.S. healthcare system by finally acknowledging that evidence-based, non-drug options can play a key role in medical care," said Alon Ironi, CEO and Co-Founder of Theranica. "With more than one in two Americans now holding covered access to this therapy, clinicians treating migraine patients can focus on clinical and patient-centered choices without concern for added economic strain on those patients."

This success positions Nerivio as the first and only FDA-cleared non-drug migraine treatment with broad commercial insurance coverage outside the Veterans Health Administration. For the nearly 39 million Americans affected by migraine, this expanded coverage marks a meaningful advance toward wider access to innovative, evidence-supported therapies.

The growing reimbursement base reflects rising demand for safe, effective non-drug options and greater use of Nerivio in contemporary migraine care. As access widens, providers are incorporating Nerivio into both acute and preventive strategies, helping define a fresh standard in migraine treatment.

"Insurance coverage stands as one of the biggest influences on patient access to migraine care," said Noah Rosen MD, FAHS, FANA, FAAN, Director of the Headache Center of Northwell Health in New York. "It is vital that insurers broaden choices for clinicians and patients facing this severe chronic neurological condition by including evidence-based, FDA-cleared therapies in their formularies. Wider reimbursement supports decisions driven by clinical needs instead of coverage limits."

Prescribed patients whose plans do not yet cover Nerivio may qualify for a Patient Assistance Program aimed at lowering out-of-pocket expenses. The program underscores the company's dedication to broadening access to evidence-based migraine care as reimbursement expands further.

About Nerivio

Nerivio is the first and only FDA-cleared prescription Remote Electrical Neuromodulation (REN) therapy approved for both acute and preventive migraine treatment, setting a new care standard. Backed by over 35 peer-reviewed published clinical studies, including multiple randomized controlled trials and large real-world evidence analyses, Nerivio has shown reliable efficacy, a strong safety record, and practical effectiveness.

Worn on the upper arm, Nerivio engages the body's natural pain control pathways through Conditioned Pain Modulation (CPM) to provide focused drug-free relief. Approved for patients aged 8 and older, it delivers patented electrical pulses without needles, systemic effects, or drug interactions. Managed via a smartphone app, Nerivio supports targeted on-demand treatment that fits real-life migraine patterns, offering relief during attacks and lowering frequency with preventive use.

About Theranica

Theranica is a growth-stage neuromodulation therapeutics company reshaping migraine and other complex idiopathic pain conditions through its proprietary Remote Electrical Neuromodulation (REN) technology. Rooted in Conditioned Pain Modulation (CPM) science, REN selectively activates the body's natural pain-inhibitory pathways to deliver clinically proven drug-free relief.

Theranica is extending REN past migraine as a scalable mechanism, building a pipeline of effective, reimbursed non-pharmacologic options for patients with a wider range of chronic pain conditions.

Media Contact

Kris Barr
Executive Director, Public Relations and Investor Relations
Theranica
[email protected]
+1 410.919.7889

SOURCE Theranica